The Drug Delivery Market in 2026

Global drug delivery technology is valued at $54.24 billion in 2025, rising to $60.27 billion in 2026, an 11.1% year-on-year jump, and is forecast to reach $91.41 billion by 2030 at roughly 11% CAGR, according to ResearchAndMarkets' Drug-Delivery Technology Market report. That growth rate outpaces most adjacent healthcare categories, driven by chronic disease prevalence, the shift toward injectable biologics, and patient demand for at-home rather than in-clinic administration.

Zoom into specific device categories and the numbers get larger still. The broader drug delivery devices market, which includes autoinjectors, inhalers, transdermal patches, and implantable pumps, is projected to reach $949.21 billion by 2035, per SNS Insider's 2035 forecast. Smart, connected delivery systems, devices with sensors, dose logging, or app connectivity, are estimated to reach $262.13 billion by 2025 on their own, according to Towards Healthcare's smart drug delivery market sizing.

Within that, large-volume wearable injectors, the on-body devices used to deliver high-viscosity biologics that syringes can't handle, are a smaller but fast-growing slice, projected to reach $1.5 billion by 2030 as more biologics move from clinical to commercial phase, per ONdrugDelivery's analysis of next-generation wearable delivery devices. Most operators in this space stop describing the market as "biotech" broadly; the number that actually moves a plan forward is the specific device category and delivery route you're targeting, because that determines which regulatory pathway, which CDMO relationships, and which reimbursement codes apply.

Growth Drivers Behind the Numbers

Three forces sit behind the 11%+ CAGR figures cited above. First, the injectable biologics pipeline keeps growing, monoclonal antibodies, GLP-1 therapies, and gene/cell therapies are almost all delivered by injection, and many are high-viscosity or large-volume formulations that standard syringes can't handle well, which is exactly the gap wearable and connected injectors fill. Second, payers and health systems are actively pushing care out of clinics and into patients' homes to cut cost-per-treatment, which favours self-administration devices over infusion-suite-only therapies. Third, chronic disease prevalence keeps rising across most developed markets, extending the treatment duration, and therefore the device volume, per patient. A business plan that ties its market-sizing section to one or more of these three drivers, rather than citing the headline CAGR alone, reads as far more credible to a reviewer who has seen dozens of generic "the market is growing" pitches.

Who's Already Building in This Space

Market-size figures only mean something once you can point to companies actually operating at each stage of the category. On the wearable-device side, Enable Injections built its enFuse On-Body Platform specifically to handle biologics too viscous for a standard prefilled syringe, while Eitan Medical's Sorrel platform targets the same large-volume subcutaneous niche from a different mechanical approach. SteadyMed took a different route again, building its Trevyent product around a proprietary "e-cell" expanding-battery mechanism to deliver treprostinil continuously over 24 hours for pulmonary arterial hypertension patients, a reminder that "drug delivery" covers everything from once-off injectors to always-on infusion. Fact.MR's separate Drug Delivery Systems Market report tracks this fragmentation across oral, injectable, transdermal, and implantable routes, each with its own growth curve and its own regulatory nuance.

Geographically, the wearable injector segment specifically skews North American: more than half of active companies are based in North America, with roughly 30% in Europe and the remainder split across Asia-Pacific and other regions. That matters for a business plan's go-to-market section, a UK-founded delivery company pitching a US biopharma licensing partner should expect the partner to benchmark them against a mostly-American competitive set, not a UK one.

SBA & Grant Funding Benchmarks

Life sciences R&D businesses borrow differently to the average small business, and lenders underwrite them differently too. Under NAICS 541711 (Research and Development in Biotechnology), the average approved SBA loan size runs around $529,000 based on 182 approved loans, well above the national SBA average of roughly $340,000 across all industries. The related code NAICS 541714 (biotechnology R&D excluding nanobiotechnology) carries an SBA employee-count size standard of 1,000 staff, which is generous enough that most drug delivery startups qualify for SBA programmes for years after founding.

That said, SBA 7(a) loans are rarely the first or only capital source for a device-led drug delivery business. In practice, founders stack: non-dilutive grant funding (SBIR/STTR in the US, Innovate UK smart grants in the UK), an SBA 7(a) or Start Up Loan for working capital and equipment, and equity from angels or specialist life-science seed funds once there's device or preclinical data to show. Global biotech and pharma funding topped $13.1 billion in 2025, and Series A rounds recovered to a median of $50–$80 million in 2025–2026 after a constrained 2023–2024, though most of that capital concentrates in companies with clinical-stage drug candidates rather than pure device or delivery-platform plays, which is exactly why a delivery-focused company's financial narrative needs to show lenders and grant panels a nearer-term, non-dilutive path to revenue.

A business plan for an SBA or grant application in this space should show: the specific NAICS code and why it applies, a device-specific capital-use breakdown (not a generic "equipment and working capital" line), and a realistic timeline to first revenue that accounts for the FDA or MHRA review windows described later in this guide.

Grant applications in particular reward specificity over ambition. Innovate UK smart grant panels and SBIR reviewers both score technical feasibility heavily, which means a plan that names your device class, cites the specific 510(k) predicate device or MDR classification rule you expect to fall under, and shows a design-freeze-to-submission Gantt chart will consistently outperform a plan that talks about "revolutionary drug delivery technology" in the abstract. Reviewers read hundreds of applications; the ones that get funded read like they were written by someone who has already done the regulatory homework, not someone hoping the panel won't ask.

What It Costs to Launch a Drug Delivery Business

Starting a biotech drug delivery business typically requires $250,000 to $1,800,000 in the US, or £200,000 to £1,400,000 in the UK, a far wider band than most other business plan categories because the model varies so much between a device-only CDMO relationship and a full combination-product platform with its own IP.

Cost Breakdown

• Device engineering & ISO 13485 design controls: $60,000–$220,000 (£48K–£175K)
• Preclinical & analytical/stability testing: $40,000–$180,000 (£32K–£145K)
• FDA 510(k) submission fee (FY2026): $26,067 standard / $6,517 small-business rate
• EU MDR CE marking (Class IIa–III): €32,000–€600,000+ depending on device class
• Contract manufacturing tooling & pilot run: $80,000–$500,000 (£65K–£400K)
• IP filing (device + formulation patents): $15,000–$60,000 (£12K–£48K)
• Working capital (9–12 months, pre-revenue): $100,000–$400,000 (£80K–£320K)

Funding Routes

In the US, SBA 7(a) loans cover up to $5M with terms up to 25 years, and biotech R&D loans under NAICS 541711 average $529K, well above the national norm, because lenders recognise that device and formulation work carries higher upfront capital needs than a typical small business. Our bespoke business plan service includes SBA-compliant formatting and lender-ready financial projections built around your specific regulatory pathway. In the UK, the Start Up Loans scheme offers up to £25,000 at 6% fixed interest with free mentoring, usually a bridge alongside an Innovate UK smart grant rather than the primary capital source for a device-led venture. See our industry-specific template for a funding-stack worksheet you can adapt to your own capital plan.

Phasing Capital Instead of Raising It All at Once

Few investors or lenders will fund the full $250K–$1.8M range in a single tranche, and few founders should want them to. A more fundable structure phases capital against milestones: an initial £45K–£150K of founder, grant, or friends-and-family capital to reach design freeze and a working prototype; a £180K–£400K seed or Innovate UK smart grant round to fund preclinical testing, CDMO tooling, and the first regulatory submission; and a larger £500K–£1.4M Series A or SBA-backed round to fund pilot production, CE marking or PMA-level review, and the first commercial batch. Structuring the ask this way, rather than a single lump sum, gives investors clear go/no-go checkpoints and gives you a business plan that reads as de-risked rather than speculative.

Key Hires and When to Make Them

Founders frequently under-budget the people side of a drug delivery startup because the early team looks like a generic startup team, a technical founder, maybe a co-founder on the commercial side. But the two hires that most affect fundability arrive earlier than most founders expect. A part-time or fractional regulatory affairs lead, brought on around the design-freeze stage rather than just before submission, is what catches a wrongly-assumed 510(k) pathway before it costs six months of rework. A quality lead responsible for the ISO 13485 QMS should be in place before your first CDMO engagement, because most contract manufacturers won't finalise a manufacturing agreement without visibility into your quality system. Both roles can be contracted rather than hired full-time in the first 18 months, but leaving them out of the cost breakdown entirely, a common gap in first-draft plans, understates burn rate by roughly $40,000–$120,000 a year depending on scope.

Contract Manufacturers & Device Partners to Know

Almost no first-time drug delivery founder builds every part of their device in-house. Most license or contract out injector mechanics, fill-finish, and sterile packaging to established CDMOs, then focus their own capital and IP on the formulation, dosing algorithm, or connected software layer that differentiates the product. Knowing which CDMOs cover which capability before you write your operations plan changes how you budget and how you talk to investors about build-vs-buy decisions.

• Phillips-Medisize (a Molex company): full-service design, development, and manufacturing for autoinjectors, pen injectors, inhalation devices, and wearable systems, from small volumes through commercial scale
• Stevanato Group: broad device manufacturing including pen injectors, autoinjectors, and on-body delivery systems, plus contract manufacturing services for companies that don't want to own tooling
• Nemera: established player in the drug delivery device contract manufacturing space, commonly evaluated alongside Phillips-Medisize and Stevanato for autoinjector programmes
• Enable Injections: creator of the enFuse On-Body Platform, specialising in high-volume wearable drug delivery for biologics that require larger-volume subcutaneous administration
• Eitan Medical: developer of the Sorrel wearable injection platform for subcutaneous administration of large-volume, high-viscosity medications
• West Pharmaceutical Services: components and containment systems (stoppers, seals, prefilled syringe systems) that most device programmes need regardless of which CDMO builds the injector itself
• CeQur: wearable drug delivery specialist, illustrative of the smaller, more focused device companies competing alongside the larger CDMOs

The autoinjector contract manufacturing segment alone is projected to reach $2.80 billion by 2030, which tells you how much of the drug delivery industry's actual manufacturing capacity sits with these handful of specialist CDMOs rather than with the biotech companies whose brand appears on the packaging. Your business plan's operations section should name which of these categories (or named partners) you intend to work with and why, vague references to "a manufacturing partner" read as under-researched to both investors and grant reviewers.

Build-vs-buy decisions usually come down to volume and differentiation. If your IP sits in the mechanical design of the injector itself, licensing that design to a CDMO for manufacture (rather than manufacturing in-house) preserves capital and lets you scale through an already-validated production line. If your IP sits in the formulation or a software/connectivity layer, the injector mechanics are commodity enough that partnering with West Pharmaceutical Services or a similar components supplier for standard containment systems, then contracting assembly to Nemera or Stevanato, is usually faster and cheaper than building tooling from scratch. Either way, get a CDMO capacity and lead-time quote before you finalise your operations timeline, quoted lead times routinely shift once a CDMO sees your actual device drawings.

Component sourcing is worth a separate line in your operations plan rather than folding it into a generic "materials" figure. Primary containment components, glass syringes, elastomer stoppers, and seals sourced from suppliers like West Pharmaceutical Services , typically carry minimum order quantities in the tens of thousands of units once you move from prototype to pilot production, which means your first production commitment is often larger, and more expensive, than founders initially model. Building a small buffer into your pilot-run budget for component MOQs is a cheap way to avoid a funding gap discovered mid-build.

Revenue Model & Unit Economics

Drug delivery revenue rarely comes from a single stream. Most businesses in this category blend: device or combination-product sales, platform licensing fees paid by pharma partners per approved molecule, CDMO/fill-finish service fees, and milestone-plus-royalty payments from biopharma licensing deals. Net margins swing from roughly 6% up to 26% depending on where a company sits on that spectrum, most early-stage delivery ventures run at a loss through preclinical and regulatory milestones, then flip to 20%+ margins once a platform is licensed or a device reaches meaningful commercial volume.

A worked example: a wearable subcutaneous delivery platform licensed to a single biopharma partner for one approved biologic can generate a $2M–$8M upfront licensing fee, plus an ongoing $150,000–$400,000 per-batch device supply fee once the combination product reaches commercial volume, for instance, 50,000 units a year at a $3–$8 device margin per unit works out to roughly $150,000–$400,000 in annual device-side revenue. On top of that, royalties on the drug side typically run 3–8% of net drug sales, which is where the real long-term upside sits if the underlying molecule succeeds commercially.

This blended model matters for how you build financial projections: a plan that shows only device unit sales understates the business, while one that assumes licensing income without a credible partner pipeline overstates it. Reviewers, whether an SBA underwriter, an angel investor, or an Innovate UK grant panel, expect to see each revenue line tied to a specific milestone (design freeze, 510(k) clearance, first commercial batch) rather than a flat month-by-month ramp.

For comparison, a CDMO-style operator running fee-for-service assembly for third-party drug delivery programmes builds a very different-looking model: revenue is closer to $80–$220 per unit assembled depending on device complexity, with gross margins in the 25–35% range once a production line is running at utilisation, but almost no royalty upside because the IP, and therefore the long-term value capture, sits with the client, not the manufacturer. It's a lower-risk, lower-ceiling model than platform licensing, which is exactly why it tends to be the easier of the two to finance with an SBA loan rather than equity: lenders can underwrite contracted, near-term unit economics far more confidently than a royalty stream that depends on someone else's drug reaching commercial approval.

Which Business Model Fits: Platform, Device-Maker, or CDMO?

Most first-time founders default to describing themselves as "a drug delivery company" without picking a lane, and that vagueness shows up as weak financial projections. There are really three distinct models, and each has a different cost structure and a different buyer. A platform licensor owns proprietary device or formulation IP and earns upfront fees plus royalties from pharma partners, capital-light once the platform is proven, but slow to first revenue because it depends on landing a partner. A device manufacturer sells hardware directly, either to pharma companies as a component or to health systems and patients as a finished product, faster to revenue but far more capital-intensive because you're carrying inventory, warranty, and post-market surveillance obligations yourself. A CDMO-style operator manufactures to other companies' specifications for a service fee: it's the least IP-dependent model, and often the most bankable for an SBA loan because revenue is contracted and predictable, but it also caps your margin ceiling well below what a successful platform licence can return. Naming which of these three you are, explicitly, in your executive summary is one of the fastest ways to make a drug delivery business plan read as credible rather than aspirational.

Selling Beyond the US and UK

A plan that stops at US and UK market entry leaves real revenue on the table, and reviewers familiar with the sector will notice the gap. Health Canada operates its own medical device licensing process broadly aligned with, but not identical to, the FDA framework, and is a common third market for device-led delivery businesses because of the regulatory overlap with US submissions. Australia's Therapeutic Goods Administration (TGA) recognises certain overseas approvals under its Comparable Overseas Regulator pathway, which can shorten the path to market once you already hold FDA clearance or EU CE marking. For a plan seeking investment rather than a first-market SBA loan, naming a second or third jurisdiction, and being honest that it comes after, not instead of, your primary US/UK/EU submissions, signals genuine commercial ambition without overstating near-term revenue.

Regulatory Pathways: FDA, MHRA & EU MDR

United States

• Combination Product Designation: FDA's Office of Combination Products issues a Request for Designation (RFD) within 60 days, determining whether your product follows a device-led or drug-led review track
• 510(k) Premarket Notification (device-led products): $26,067 standard fee / $6,517 small-business fee for FY2026, with a 90-day review target that often runs 6–12 months in practice
• PMA (Premarket Approval) for higher-risk Class III devices: $540,838 standard fee under the FY2026 MDUFA schedule, 180-day target, typically 1–2 years including deficiency-response cycles
• ISO 13485-certified quality management system covering design controls, risk management, and manufacturing
• Human factors / usability engineering evidence under IEC 62366, expected earlier in development rather than as an afterthought

United Kingdom

• Register the device with the MHRA, from 1 April 2026 this is an annual fee of £300 per GMDN Level 2 category rather than a one-off charge (previously £240 flat)
• UKCA or CE marking must be secured before MHRA registration, registration is not a substitute for device marking
• MHRA quotes a five-business-day review target, though this can extend if there's a backlog
• Registration renewal required one year after grant, then every two years thereafter
• Overseas manufacturers must retain a UK-based Responsible Person / in-country representative

European Union

CE marking under the EU MDR runs through Notified Body assessment. Costs scale sharply with device class: Class I self-declared devices run roughly €8,000–€26,000 including QMS documentation, Class IIa devices €32,000–€110,000, and Class III devices requiring clinical investigations can exceed €600,000. Total certification typically lands between €200,000 and €600,000, with a review timeline of 12–18 months (some Class IIa devices have cleared in as little as 11 months, though that's below the typical range). Ongoing post-market surveillance and vigilance activity adds €18,000–€48,000 a year depending on device complexity, a line item first-time founders frequently leave out of their financial model entirely.

Why the Pathway Choice Drives Everything Else

It's worth restating because so many first drafts get this backwards: the combination-product designation isn't a compliance checkbox you handle after the business plan is written, it's an input to the plan. A device-led 510(k) pathway generally means a shorter runway to first revenue but a ceiling on how novel your delivery mechanism can be, because 510(k) clearance depends on demonstrating substantial equivalence to an existing predicate device. A drug-led NDA/BLA pathway allows more genuinely novel delivery mechanisms but ties your timeline to the drug's own clinical trial programme, which can run three to seven years longer. Founders who request the FDA's Request for Designation determination in month one, rather than assuming their preferred pathway, consistently build more fundable plans, because every subsequent cost estimate, hiring plan, and revenue projection depends on knowing which track applies.

Common Mistakes First-Time Founders Make

These aren't hypothetical, they're the recurring pattern we see across regulatory-pathway and licensing-heavy business plans, and they surface at exactly the moment a founder can least afford them: during investor or lender due diligence, when a reviewer asks a single pointed question and the plan's underlying assumptions don't hold up.

• Building the device before locking the regulatory pathway. Whether your combination product is device-led (510(k)/PMA) or drug-led (NDA/BLA with device components reviewed alongside) changes your entire budget, timeline, and even your choice of CDMO. Get the FDA designation determination early.
• Underestimating CDMO lead times. Tooling and pilot production runs at contract manufacturers like Nemera, Stevanato, or Phillips-Medisize routinely take 9–14 months from design freeze, plans that show manufacturing starting "next quarter" rarely survive investor diligence.
• Treating MHRA registration as a substitute for UKCA/CE marking. It's a prerequisite step, not an alternative one, device marking has to happen first.
• Modelling revenue as pure device sales. Most delivery ventures actually get paid through a blend of licensing, milestone, and royalty income; a device-sales-only model understates both the opportunity and the credibility of the plan.
• Deferring human factors/usability engineering. Leaving IEC 62366 usability work until late in development is one of the most common causes of a costly redesign after FDA feedback.
• Not budgeting for post-market obligations. EU MDR vigilance and surveillance costs (€18,000–€48,000/year) and MHRA's annual per-category registration fee are recurring, not one-off, plans that only cost the initial certification understate their true burn rate.
• Picking a business model implicitly rather than explicitly. Founders who don't decide up front whether they're a platform licensor, a device manufacturer, or a CDMO-style operator end up with financial projections that blend assumptions from all three, which reads as confused rather than ambitious to a reviewer.

None of these are fatal on their own, but they compound: a mis-scoped regulatory pathway pushes out your CDMO timeline, which pushes out your first-revenue date, which undermines the financial model an investor or SBA lender is underwriting against. Sequencing the plan correctly (designation, then design freeze, then CDMO engagement, then submission) is worth more to your fundability than almost any other single decision.

Sample Business Plan Preview

Here's an extract from a business plan structure our team builds for drug delivery clients, so you can see exactly what you'll get:

What's in the Template

Every Avvale business plan template includes these sections, pre-structured for your industry:

• Executive Summary, Your business at a glance, written to hook investors and grant panels in 60 seconds
• Company Overview, Legal structure, IP position, and founding story
• Industry Analysis, Market size, growth trends, and the regulatory pathway that applies to your device
• Customer Analysis, Target biopharma partners, procurement criteria, and licensing decision-makers
• Competitor Analysis, CDMO and platform-company mapping, plus your differentiation strategy
• Marketing Plan, Channels, positioning, and partner acquisition strategy for a B2B licensing model
• Operations Plan, Device development milestones, CDMO relationships, and regulatory submission timeline
• Management Team, Founder bios, technical advisory board, and key hires planned

The optional Financial Forecast add-on (included in our $300/£250 and $1,000/£800 packages) provides a 5-year Excel model with income statement, cash flow, balance sheet, break-even analysis, and startup capital requirements, built to reflect a blended licensing-plus-device revenue model rather than a generic single-revenue-line template. See also our biotech drug discovery business plan template if your company sits earlier in the pipeline, or our pharmaceutical drug development business plan template if you're further along toward an NDA/BLA filing.

Because drug delivery plans get read by such a mixed audience, grant panels scoring technical feasibility, angel investors scoring commercial upside, and SBA underwriters scoring repayment capacity, we build in a regulatory pathway appendix as standard for this category, mapping your specific device class to the FDA and MHRA/EU MDR timelines and fees set out earlier in this guide, rather than leaving reviewers to look that detail up themselves.

Frequently Asked Questions